Chimeric Therapeutics
Wednesday, June 05, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
Chimeric Therapeutics, is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer.
Chimeric is developing two first in class autologous CAR T cell therapies and a potentially best in class allogeneic NK cell therapy platform.
Chimeric assets are being investigated across multiple different disease areas in oncology including Colorectal Cancer, Gastric Cancer, Neuroendocrine Tumors, Acute Myeloid Leukemia and Glioblastoma.
Chimeric has presented positive preliminary data for two of their platforms, CHM 1101, a CLTX CAR T cell therapy in recurrent Glioblastoma and CHM 0201, an NK cell therapy platform in Acute Myeloid Leukemia.
Chimeric has 3 ongoing Phase 1B clinical programs and plans to open an additional Phase 1A clinical program in 2024.
Chimeric is currently listed on the ASX, with full operations in the United States.
Company Website:
http://www.chimerictherapeutics.com
Lead Product in Development:
CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumors. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.
CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) received IND clearance in November 2023, with a planned phase 1A clinical trial in Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumors scheduled to open in mid-2024.
CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating expansion, persistence and safety and efficacy in Acute Myeloid Leukemia. Two Phase 1B clinical trials are ongoing exploring CHM 0201 in combination with Vactosertib and with Azacitidine / Venetoclax in Acute Myeloid Leukemia.
CHM 0201 is also being further developed as a next generation engineered NK cell platform (CHM 0301) and as CAR NK cell therapies (CHM 1301 and CHM 2301). Positive preclinical data has been presented for CHM 0301 and CHM 1301.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3 platform technologies seeking partners
Exchange
ASX
Ticker
CHM
Company HQ City
Carlton
Company HQ State
Victoria
Company HQ Country
Australia
CEO/Top Company Official
Jennifer Chow, CEO and Managing Director
Development Phase of Primary Product
Phase I
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())